Cara Therapeutics Inc (NAS:CARA)
$ 0.2908 -0.0132 (-4.34%) Market Cap: 15.95 Mil Enterprise Value: -21.94 Mil PE Ratio: 0 PB Ratio: 29.08 GF Score: 33/100

Cara Therapeutics Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript

May 14, 2020 / 01:00PM GMT
Release Date Price: $15.08 (+6.65%)
Jason Matthew Gerberry
BofA Merrill Lynch, Research Division - MD in US Equity Research

Good day, everybody. My name is Jason Gerberry. I -- well, first off, I want to thank everybody for joining us for day 3 of the Bank of America Virtual Healthcare Conference. I'm the SMID cap, biotech and specialty pharma analyst at Bank of America, and I'm pleased to be introducing our next company presenter, Cara Therapeutics and CEO, Derek Chalmers. For those on the line, Cara is developing therapeutics for pruritus or itch that tends to be more moderate to severe in nature. The company recently reported positive Phase III data from its second confirmatory trial for KALM-2 for end-stage renal disease, patients who are suffering from itch, and the company is also exploring applications of this small AD in an oral formulation. And so we'll be looking to talk upon each of these topics today with Derek.

So first off, Derek, thanks so much for joining us.

Derek T. Chalmers
Cara Therapeutics, Inc. - Co-Founder, President, CEO & Director

Good morning, Jason.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot